Thursday, 20 January 2022
Arbutus Biopharma Corporation
Analysts expect Arbutus Biopharma Corporation (NASDAQ:ABUS) to report $-0.38 EPS on March, 20.They anticipate $0.00 EPS change or 0.00 % from last quarter's $-0.38 EPS.
more»14:52 | 5/3/18
Danvers Record
Arbutus Biopharma Corporation (NasdaqGS:ABUS) currently has a current ratio of 11.03. The current ratio, which is also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the ...
more»13:11 | 3/3/18
Frisco Fastball
Analysts expect Arbutus Biopharma Corporation (NASDAQ:ABUS) to report $-0.38 EPS on March, 20.They anticipate $0.00 EPS change or 0.00 % from last quarter's $-0.38 EPS.
more»06:37 | 3/3/18
The Ledger Gazette
Arbutus Biopharma logo Hudson Bay Capital Management LP lifted its holdings in shares of Arbutus Biopharma Corp (NASDAQ:ABUS) by 239.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and ...
more»01:33 | 2/3/18
Frisco Fastball
Analysts expect Arbutus Biopharma Corporation (NASDAQ:ABUS) to report $-0.38 EPS on March, 20.They anticipate $0.00 EPS change or 0.00 % from last quarter's $-0.38 EPS.
more»Analysts expect Arbutus Biopharma Corporation (NASDAQ:ABUS) to report $-0.38 EPS on March, 20.They anticipate $0.00 EPS change or 0.00 % from last quarter's $-0.38 EPS.
more»15:36 | 14/2/18
GlobeNewswire
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that Bruce Cousins, Executive ...
more»14:52 | 29/1/18
The Ledger Gazette
Arbutus Biopharma logo Arbutus Biopharma (NASDAQ:ABUS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, January 3rd.
more»12:15 | 24/1/18
The Ledger Gazette
Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) have been assigned a consensus rating of “Hold” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports.
more»02:30 | 17/1/18
GlobeNewswire
VANCOUVER, British Columbia and WARMINSTER, Pa., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today announced the closing of the issue and sale ...
more»
| Code | Last | Change |
|---|
| COMP | 14,823 | 252 |  | 1.73% |
| DJI | 34,913 | 535 | | 1.56% |
| SP500 | 4,438 | 74 | | 1.71% |
| DAX | 15,463 | 213 | | 1.40% |
| FTSE | 7,488 | 5 |  | 0.07% |
| NI225 | 22,420 | 408 | | 1.86% |
| TWI | 74.32 | 0.00 |  | 0.00% |